Company Filing History:
Years Active: 2025
Title: Thomas C J Mies: Innovator in KRAS Modulation
Introduction
Thomas C J Mies is a notable inventor based in Burlingame, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target specific mutations in the KRAS gene.
Latest Patents
Mies holds a patent for "KRAS G12D modulating compounds." This patent includes compounds and pharmaceutically acceptable salts that serve as inhibitors for KRAS G12D and/or KRAS G12C. The patent outlines methods for making and using these compounds, either alone or in combination with additional agents, as well as the pharmaceutical compositions derived from them.
Career Highlights
Currently, Thomas C J Mies is associated with Gilead Sciences, Inc., a leading biopharmaceutical company. His work focuses on innovative approaches to combat cancer through targeted therapies.
Collaborations
One of his notable coworkers is Chaodi Dai, with whom he collaborates on various projects related to KRAS modulation.
Conclusion
Thomas C J Mies exemplifies the spirit of innovation in the pharmaceutical industry, contributing valuable research that may lead to effective cancer treatments.